| Journal | The New England Journal of Medicine (NEJM) |
| Volume / Issue | Vol. 394, No. 10 — March 5, 2026 |
| Type | Clinical Decisions (Interactive Format) |
| DOI | 10.1056/NEJMclde2505268 |
| Case Author | Christos P. Kotanidis, M.D., D.Phil. — Univ. of Oxford |
| Expert 1 | Paul K. Whelton, M.B., M.D. — Tulane University |
| Expert 2 | Clinton B. Wright, M.D. — NINDS / NIH |
| References | 9 sources (2015–2026) |
1. Article Format and Type
This article is an interactive clinical decision format belonging to NEJM’s ‘Clinical Decisions’ series. This format is presented in a structure where two experts defend different positions assigned by the editors based on a real patient case, after which readers can express their opinions. The format does not prescribe a clear ‘correct answer’; the goal is to improve the decision-making processes of clinicians and reveal the distribution of opinions within the medical community.
Features of the Format
- Realistic, context-rich clinical case presentation
- Two experts defend assigned positions (debate format)
- Community opinion is formed via a reader poll
- Editorial independence is maintained; no single option is declared ‘correct’
2. Clinical Case Summary
A 75-year-old male patient presents for routine follow-up. His physical activity is limited due to chronic joint pain; this situation is of critical importance regarding both his cardiovascular risk profile and medication tolerability.
2.1. Patient’s Baseline Characteristics
| Parameter | Value | Clinical Significance |
|---|---|---|
| Age / Gender | 75 years / Male | Elderly patient; orthostatic risk increases |
| Office BP | 138/86 mmHg | Borderline of target range |
| Home BP Average | 136 mmHg (SBP) | Consistent, reliable measurement |
| 10-year CVD risk | 17.6% (Framingham) | High-risk category |
| Orthostatic SBP drop | −11 mmHg (at 3rd min) | Sub-threshold (20 mmHg), but significant |
| History of falls | 2 times / 6 months (morning) | Suggests an orthostatic origin |
| Current antihypertensives | Ramipril + Amlodipine | Dual-agent therapy |
| Additional medications | Atorvastatin 40 mg, NSAIDs (occasional) | NSAIDs can slightly elevate BP |
| Comorbidities | Chronic joint pain | Activity limitation, NSAID use |
| Cholesterol profile | LDL: 200 mg/dL, HDL: 65 mg/dL | Statin therapy ongoing |
3. Clinical Decision Options
Two experts have been assigned by the editors to advocate for different treatment targets. Below are the core arguments of both positions presented comparatively.
3.1. Option 1: SBP < 120 mmHg Target
Advocate: Paul K. Whelton, M.B., M.D. (Tulane University, Public Health)
- Large-scale meta-analysis: A <120 target reduces major CVD events by 18% and all-cause mortality by 13% compared to a <140 mmHg target.
- Associated with better cognitive function and a 15% lower risk of dementia (He 2025, Nature Medicine).
- Similar CVD protection was achieved in patients with orthostatic hypotension (Juraschek 2023, JAMA).
- Single-pill combination regimens (dual/triple) increase treatment adherence and provide targeted BP reduction.
- Isometric resistance exercises (wall sits, yoga) can lower SBP by >8 mmHg without putting a load on the joints.
- NSAID use only increases SBP by <5 mmHg; it remains at a manageable level.
3.2. Option 2: SBP < 140 mmHg Target
Advocate: Clinton B. Wright, M.D. (NINDS / NIH, Bethesda)
- The patient’s current BP value is within the target range of many national and international guidelines; <120 mmHg is only recommended in Canadian and Australian guidelines.
- The SPRINT trial was stopped early, and the number of participants at this patient’s BP level is insufficient for a definitive comparison.
- Although the diagnostic threshold for orthostatic hypotension (20 mmHg) is not met, the possibility of autonomic dysfunction exists; further diagnostic evaluation is required.
- BP variability and hypotensive episodes are associated with cognitive decline, which could increase with intensive treatment (Zhang 2025, Hypertension).
- Patients with neurogenic orthostatic hypotension have been underrepresented in existing studies.
- Diagnostic steps such as ambulatory BP monitoring and the Valsalva maneuver should be completed first.
4. Core Evidence Base
| Study / Source | Findings and Significance |
|---|---|
| SPRINT RCT (Wright 2015, NEJM) | Intensive treatment was shown to reduce CVD and mortality; stopped early. Statistical power is insufficient for the BP sub-group in this case. |
| Meta-analysis (Whelton 2026, Curr Opin Nephrol) | Demonstrated clear superiority of a <120 mmHg target vs. <140 in high-risk elderly patients (18% CVD reduction). |
| SPRINT Revisited (Wright 2021, Hypertension) | Updated SPRINT results; data on cognitive benefits and white matter lesion progression. |
| JAMA Meta-analysis(Juraschek 2023) | Indicated that intensive treatment maintained its CVD advantage in patients with orthostatic hypotension; noted that neurogenic OH is underrepresented. |
| Nature Medicine (He 2025) | Open-label cluster RCT: BP lowering shown to reduce all-cause dementia by 15% in people with uncontrolled hypertension. |
| BJSM Meta-analysis(Edwards 2023) | Large-scale network meta-analysis showing isometric resistance training is more effective on resting BP than aerobic/dynamic exercise. |
| Maturitas (Duval 2024) | Systematic review and meta-analysis showing the association of orthostatic hypotension with cognitive impairment. |
| Hypertension (Zhang 2025) | SPRINT post-hoc: Shown that hypotensive episodes on 24-hour ambulatory BP negatively affect cognitive processing speed. |
5. Alignment with Guidelines
| Guideline | Target for Elderly Patients | Relation to This Case |
|---|---|---|
| 2025 AHA/ACC (USA) | <130/80 mmHg (>10% ASCVD risk) | The patient’s 17.6% risk meets this category; a middle ground between the options |
| ACC-AHA 2017 | <130/80 mmHg | Current treatment is above this target |
| ESC/ESH 2018 (Europe) | 70-79 years: <130-139 mmHg | The patient’s BP range complies with this guideline |
| Canadian Guideline | <120 mmHg (high risk) | Supports Option 1 |
| Australian Guideline | <120 mmHg (high risk) | Supports Option 1 |
| JNC 8 (USA, older) | ≥60 years: <150/90 mmHg | Outdated; too relaxed for this case |
Important Guideline Note: The 2025 AHA/ACC guideline recommends a <130/80 mmHg target for all older adults with a 10-year ASCVD risk >10%. This value forms a middle ground between the two options discussed in the article and is not directly compared due to the constraints of the editorial format.
6. Orthostatic Hypotension: Critical Diagnostic Evaluation
The most nuanced debate of the article shapes around orthostatic hypotension. The patient remains below the technical diagnostic threshold (>20 mmHg drop), but clinical findings suggest autonomic dysfunction.
6.1. Diagnostic Algorithm (Wright’s Suggestion)
- 10 minutes supine position → standing up → 3 minutes BP and heart rate measurement
- Valsalva maneuver: slow BP recovery, no compensatory tachycardia in neurogenic failure
- 24-hour ambulatory BP monitoring: investigation of nocturnal BP and ‘non-dipping’ pattern
- Symptom inquiry: heat intolerance, postprandial dizziness, neck pain (‘coat hanger’ pattern), olfactory impairment
- Rhythm monitoring for cardiac arrhythmias (e.g., atrial fibrillation)
6.2. Comparison of Both Experts’ Evaluations
| Whelton (Option 1) | Wright (Option 2) |
|---|---|
| 11 mmHg drop; sub-threshold → OH diagnosis is not met | 11 mmHg drop; autonomic dysfunction is still possible |
| Intensive treatment maintained CVD benefit even in patients with OH | Neurogenic OH has not been adequately represented in studies |
| 2 morning falls → manageable with careful monitoring | Falls + bruising evidence → more comprehensive evaluation needed |
| Ramipril vasodilation may mildly affect this | Ramipril + nocturnal hypertension combination may worsen OH |
7. Scientific Evaluation of the Article
7.1. Strengths
- Published in a high-impact, peer-reviewed journal; the Clinical Decisions series is one of NEJM’s most respected formats.
- Both experts base their arguments on current, high-evidence-level literature (RCTs, meta-analyses, 2025 guidelines).
- The clinical case is realistic and context-rich: multiple comorbidities, polypharmacy, elderly patient profile.
- Editorial independence is preserved; no position is explicitly declared ‘correct’.
- The reader participation mechanism reveals the true distribution of opinions within the clinical community.
7.2. Limitations and Methodological Notes
- The debate format forces experts to defend an assigned position; this may not fully reflect genuine clinical judgment.
- The SPRINT trial lacked sufficient statistical power in the subgroup close to this patient’s baseline BP value.
- A third option (e.g., <130 mmHg) was not presented; whereas the current AHA/ACC guideline dictates this.
- Patients with neurogenic orthostatic hypotension were excluded from most studies; there is no specific evidence for this population.
- Both experts cite some of their own studies or those of close colleagues (potential conflict of interest with limited impact).
8. Overall Evaluation and Conclusion
This article successfully summarizes the real clinical tension between intensive blood pressure control and safe treatment balance in hypertension management. The arguments of both experts are consistent with the literature and proceed through a dilemma frequently encountered in clinical practice.
Whelton’s position argues that population-level cardiovascular benefit outweighs individual safety concerns. Wright, on the other hand, emphasizes that this patient’s atypical autonomic profile may fall outside standard treatment protocols and requires a more comprehensive diagnostic evaluation. Both arguments are scientifically defensible.
Editor’s Note:
- Clinical Conclusion: The <130/80 mmHg target recommended by the 2025 AHA/ACC guideline forms a practical middle ground between both options. An individualized approach for this patient should include a combination of a careful BP titration plan, ambulatory monitoring, and exercise rehabilitation.
- Evidence Gap: Prospective RCTs investigating optimized BP targets for older hypertensive patients with neurogenic orthostatic hypotension are needed.
9. References
- Whelton PK, O’Connell S, Mills K, He J. Evolution in the targets for blood pressure control. Curr Opin Nephrol Hypertens 2026;35:141-9.
- Wright JT Jr, Whelton PK, Johnson KC, et al. SPRINT revisited: updated results and implications. Hypertension 2021;78:1701-10.
- He J, Zhao C, Zhong S, et al. Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension: an open-label, blinded-endpoint, cluster-randomized trial. Nat Med 2025;31:2054-61.
- Juraschek SP, Hu JR, Cluett JL, et al. Orthostatic hypotension, hypertension treatment, and cardiovascular disease: an individual participant meta-analysis. JAMA 2023;330:1459-71.
- Edwards JJ, Deenmamode AHP, Griffiths M, et al. Exercise training and resting blood pressure: a large-scale pairwise and network meta-analysis of randomised controlled trials. Br J Sports Med 2023;57:1317-26.
- Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC guideline for the prevention, detection, evaluation and management of high blood pressure in adults. Hypertension 2025 (Epub ahead of print).
- Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-16.
- Duval GT, Raud E, Gohier H, Dramé M, Tabue-Teguo M, Annweiler C. Orthostatic hypotension and cognitive impairment: systematic review and meta-analysis of longitudinal studies. Maturitas 2024;185:107866.
- Zhang W, Redline S, Viswanathan A, et al. Hypotensive episodes on 24-hour ambulatory blood pressure and cognitive function: insights from the SPRINT study. Hypertension 2025;82:627-37.
Share
